Worldwide Clinical Trials Brings Pure Science to Life in NASH Research

Nonalcoholic steatohepatitis (NASH) is a progressive condition causing inflammation and damage to the liver cells similar to the damage caused by alcoholic hepatitis. Potential complications related to NASH are cirrhosis of the liver and hepatocellular carcinoma. Because the disease is related to obesity and insulin resistance and increasingly becoming a common indication for liver transplantation, improved treatments of the condition carry positive implications for public health and the healthcare system as a whole. Current research goals focus on pathogenesis that may provide insight into diagnosis and treatment of the disease.

With its decades-long history in clinical trial design and execution, Worldwide Clinical Trials has combined scientific expertise and methodology with a personal dedication to help patients at the clinical level. We’re a full-service CRO with the expertise to incorporate both traditional and innovative study approaches, while maintaining a strong grounding in regulatory imperatives. Our award-winning approach combines patient centricity with strong investigative collaboration to arrive at optimal strategies for achieving reliable data on time and within budget.